Introduction {#S1}
============

The retina shares similarities with cerebral neurons in development, physiology, and anatomy ([@B1]--[@B3]). Retinal optical coherence tomography (OCT), a non-invasive *in vivo* optical biopsy of the retina, has enabled remarkable advances in assessing retinal ganglion cell (RGC) axons by quantifying peripapillary retinal nerve fiber layer (RNFL) damage, particularly in the field of glaucoma ([@B4]). OCT has also been used to study neurodegenerative diseases such as dementia ([@B5]). Current clinical studies have shown that RNFL measured by OCT exhibits thinning in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) ([@B6]--[@B16]). With spectral-domain OCT (SD-OCT), a greater degree of resolution and scan speed is now available to allow more detailed RGC analysis at the macular region including measurement of the ganglion cell layer that is composed of cell bodies, and the inner plexiform layer that contains the RGC dendrites ([@B17], [@B18]). It has been shown that macular ganglion cell-inner plexiform layer (GC-IPL) neuronal loss is more strongly related to MCI, compared with RNFL axonal loss, suggesting that GC-IPL thickness is a more sensitive marker than RNFL thickness for assessing neurodegenerative pathology in MCI or early AD ([@B11]).

Numerous studies have demonstrated good reproducibility and repeatability of using SD-OCT to measure RNFL and GC-IPL thicknesses in normal, glaucoma, retinal diseases as well as hypertensive eyes ([@B14], [@B19]--[@B25]). However, data on the repeatability and reproducibility in patients with cognitive dysfunction and dementia are lacking. One study reported the repeatability of OCT in measurement of retinal and RNFL thicknesses in 75 patients with AD, with satisfactory results \[mean coefficient of variation (CoV) of 4.78% and ICC of \>0.905\] ([@B26]), though the study only involved intra-visit analysis but no inter-visit analysis and no assessment of GC-IPL thickness.

It is crucial to ascertain both the intra-visit repeatability and inter-visit reproducibility of OCT measurements in patients with cognitive dysfunction, to ensure changes detected are indeed due to pathological neurodegeneration in patients with progressive cognitive impairment, rather than machine error or natural regression due to age. In this study, we assessed intra-visit repeatability and inter-visit reproducibility of macular GC-IPL and peripapillary RNFL measurement with SD-OCT in patients with cognitive impairment.

Materials and Methods {#S2}
=====================

Study Population {#S2-1}
----------------

All patients were recruited from memory clinics at the National University Hospital, Singapore, as part of an ongoing prospective study of cognitive progression. Patients were eligible to be recruited if they were diagnosed with dementia syndrome (Alzheimer's type) in accordance to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) or MCI (Petersen's criteria) ([@B27]). Subjects underwent cognitive assessment by neuropsychologists at baseline and 1-year follow-up. Assessment for severity of cognitive impairment included clinical dementia rating (CDR) scale. In the current analysis, only subjects determined to be stable (no change in global CDR score) at 1-year follow-up, with no history of glaucoma ([@B28], [@B29]), and completed OCT scans at all visits were included.

Written informed consent was obtained from each participant or his or her primary caregiver; the study conducted adhered to the Declaration of Helsinki. Ethics approval was obtained from National Healthcare Group Pte Ltd Domain Specific Review Board.

OCT Imaging {#S2-2}
-----------

After pupil dilation using tropicamide 1.0% and phenylephrine hydrochloride 2.5%, a spectral-domain OCT (Cirrus HD-OCT, software version 6.0.2, Carl Zeiss Meditec, Dublin, CA, USA) was used to obtain scans using the cube 200 × 200 and optic nerve head cube 200 × 200 scan protocols, respectively, in each eye in a darkened room. Eye-tracking function was not available in this software version. Before imaging, our trained technicians explained the details of imaging procedures and clearly instructed the subjects on how to look at the fixation target without blinking during imaging. At least two attempts per scan per eye were taken at each visit. At baseline visit, two consecutive scans were taken for each scan protocol and each eye for assessment of intra-visit repeatability. Scans were repeated at 6-month and 1-year follow-up visits for assessment of reproducibility.

After imaging, all the OCT data were sent to our reading center and reviewed by our trained graders. Assessment of each scan was made by two certified trained graders at the reading center. Adjudication was provided by retinal specialists if needed. The graders checked the quality of scan, presence of pathology, and segmentation of GC-IPL and RNFL. GC-IPL thicknesses were detected and measured automatically from a 14.13 mm^2^ elliptical annulus area centered on the fovea, from macular scans. Peripapillary RNFL thicknesses were measured automatically from a calculation circle of diameter 3.46 mm centered on the optic disk, from optic nerve head scans. An algorithm error was defined as incorrect segmentation of GC-IPL and RNFL. Scans were excluded from analysis if signal strength was less than 5, or when there was retinal pathology affecting GC-IPL or RNFL segmentation (such as epiretinal membrane, macula edema, vitreomacular traction, age-related macular degeneration, etc.), or when there was incorrect segmentation of GC-IPL or RNFL. An APOSTLE checklist for our OCT imaging was included in the Appendix in the Supplementary Material.

Statistical Analysis {#S2-3}
--------------------

Intraclass correlation coefficients (ICC) and CoV were calculated for each parameter from each SD-OCT scan with acceptable quality for analysis. Parameters assessed include macular GC-IPL (average, superotemporal, superior, superonasal, inferonasal, inferior, and inferotemporal) and peripapillary RNFL (average, temporal, superior, nasal, and inferior) thicknesses. Intra-visit repeatability was assessed using measurements from two consecutive scans performed at the baseline visit, while inter-visit reproducibility was assessed using measurements over all three visits (baseline, 6-month, and 1-year) follow-ups.

In addition, Bland--Altman plots comparing selected parameters such as GC-IPL and peripapillary RNFL average thicknesses from baseline and 1-year follow-up were used to assess for bias.

We also performed a subgroup analysis of subjects with AD and MCI, respectively, to assess if the reproducibility and repeatability was poorer in patients with either AD or MCI.

Results {#S3}
=======

A total of 61 subjects were eligible to be included in the study---32 with AD and 29 with MCI. Figure [1](#F1){ref-type="fig"} shows the flowchart of the participants included in the study. Excluded scans in this flowchart reflect subject scans that were unable to be used across all three visits. Appendices 2 and 3 in Supplementary Material show the breakdown of scans excluded from the study by eyes and the main reasons for exclusion, respectively.

![Flowchart of Participants for the overall assessment.](fneur-08-00359-g001){#F1}

Table [1](#T1){ref-type="table"} presents the distribution of subject characteristics at baseline. These subjects had SD-OCT scans with acceptable quality for either GC-IPL or RNFL (or both) measurements. For GC-IPL measures, within the 61 eligible patients, a total of 70 eyes were suitable for intra-visit analysis (37 right and 33 left), while 52 eyes had data over all three visits for inter-visit analysis (26 right and 26 left). For peripapillary RNFL measures, a total of 77 eyes were suitable for intra-visit analysis (35 right and 42 left), while 69 eyes had data over all three visits for inter-visit analysis (37 right and 32 left).

###### 

Baseline characteristics of study subjects.

  Baseline characteristics                               All subjects (*n* = 61)   Alzheimer's disease (*n* = 32)   Mild cognitive impairment (*n* = 29)
  ------------------------------------------------------ ------------------------- -------------------------------- --------------------------------------
  Age, mean (SD)                                         73.1 (8.3)                76.3 (5.5)                       69.7 (9.5)
  Male, *n* (%)                                          28 (45.9)                 13 (40.6)                        15 (51.7)
  Chinese ethnicity, *n* (%)                             45 (73.8)                 25 (78.1)                        20 (69.0)
  Hypertension, *n* (%)                                  42 (68.9)                 27 (84.4)                        15 (51.7)
  Diabetes, *n* (%)                                      23 (37.7)                 12 (37.5)                        11 (37.9)
  Hypercholesterolemia, *n* (%)                          45 (73.8)                 22 (68.8)                        23 (79.3)
  Clinical dementia rating (CDR) global = 0.5, *n* (%)   29 (47.5)                 0 (0.0)                          29 (100)
  CDR global = 1, *n* (%)                                25 (41.0)                 25 (78.1)                        0 (0.0)
  CDR global = 2, *n* (%)                                7 (11.5)                  7 (21.9)                         0 (0.0)

Table [2](#T2){ref-type="table"} shows that the means and SD of parameters from both ONH and macula scans remained similar and were not significantly different across all three visits.

###### 

Distributions of macular ganglion cell-inner plexiform layer (GC-IPL) and peripapillary retinal nerve fiber layer (RNFL) thicknesses.

  Mean (SD)                                Baseline         6-Month follow-up   1-Year follow-up   *P*
  ---------------------------------------- ---------------- ------------------- ------------------ -------
  **Macular GC-IPL parameters (μm)**                                                               
  GC-IPL average thickness                 77.44 (9.56)     77.37 (9.93)        77.13 (9.19)       0.985
  GC-IPL minimum thickness                 72.54 (12.46)    72.38 (12.67)       72.13 (12.42)      0.986
  GC-IPL temporal superior                 77.04 (10.78)    76.79 (11.13)       76.58 (9.71)       0.976
  GC-IPL superior                          78.42 (8.89)     78.17 (9.71)        77.75 (8.94)       0.932
  GC-IPL nasal superior                    79.37 (10.12)    79.15 (10.14)       79.10 (9.80)       0.990
  GC-IPL nasal inferior                    76.85 (10.23)    76.77 (10.17)       77.10 (10.20)      0.985
  GC-IPL inferior                          75.42 (10.75)    75.52 (10.87)       75.31 (10.11)      0.995
  GC-IPL temporal inferior                 77.38 (10.55)    77.48 (11.26)       76.67 (10.28)      0.915
  **Peripapillary RNFL parameters (μm)**                                                           
  RNFL average thickness                   90.77 (12.48)    90.75 (12.74)       89.54 (12.94)      0.810
  RNFL temporal quadrant                   65.87 (12.57)    66.19 (13.49)       65.88 (13.16)      0.987
  RNFL superior quadrant                   110.77 (18.65)   110.20 (17.62)      108.45 (18.17)     0.737
  RNFL nasal quadrant                      69.06 (10.75)    69.36 (10.13)       68.17 (10.76)      0.789
  RNFL inferior quadrant                   117.54 (24.38)   117.23 (24.80)      115.54 (24.78)     0.877

Intra-visit repeatability and inter-visit reproducibility of macular GC-IPL thicknesses are shown in Table [3](#T3){ref-type="table"}. For macular GC-IPL thicknesses, the range of intra-visit ICC was 0.948--0.985, and the range of CoV was 1.14--2.40%, while the range of inter-visit ICC was 0.941--0.985, and the range of CoV was 1.24--2.32%.

###### 

Intra-visit repeatability and inter-visit reproducibility of macular ganglion cell-inner plexiform layer (GC-IPL) measurement.

  Parameters                        Coefficient of variation (%)   ICC
  --------------------------------- ------------------------------ ----------------------
  **Intra-visit repeatability**                                    
  GC-IPL average thickness          1.14                           0.985 (0.976--0.991)
  GC-IPL minimum thickness          2.12                           0.962 (0.939--0.976)
  GC-IPL superotemporal             1.49                           0.983 (0.973--0.989)
  GC-IPL superior                   1.96                           0.962 (0.940--0.976)
  GC-IPL superonasal                1.51                           0.974 (0.959--0.984)
  GC-IPL inferonasal                2.33                           0.948 (0.918--0.967)
  GC-IPL inferior                   2.40                           0.954 (0.928--0.971)
  GC-IPL inferotemporal             1.56                           0.983 (0.972--0.989)
  **Inter-visit reproducibility**                                  
  GC-IPL average thickness          1.24                           0.985 (0.977--0.991)
  GC-IPL minimum thickness          1.79                           0.983 (0.974--0.990)
  GC-IPL superotemporal             1.96                           0.960 (0.938--0.976)
  GC-IPL superior                   2.32                           0.941 (0.909--0.964)
  GC-IPL superonasal                1.74                           0.977 (0.965--0.986)
  GC-IPL inferonasal                2.12                           0.960 (0.937--0.975)
  GC-IPL inferior                   2.25                           0.966 (0.946--0.979)
  GC-IPL inferotemporal             1.86                           0.975 (0.960--0.985)

Intra-visit repeatability and inter-visit reproducibility of peripapillary RNFL thicknesses are shown in Table [4](#T4){ref-type="table"}. For peripapillary RNFL thicknesses, the range of intra-visit ICC was 0.937--0.986, and the range of CoV was 1.34--2.90%, while the range of inter-visit ICC was 0.845--0.961, and the range of CoV was 2.71--5.25%.

###### 

Intra-visit repeatability and inter-visit reproducibility of peripapillary retinal nerve fiber layer (RNFL) measurement.

  Parameters                        Coefficient of variation (%)   ICC
  --------------------------------- ------------------------------ ----------------------
  **Intra-visit repeatability**                                    
  RNFL average thickness            1.34                           0.986 (0.978--0.991)
  RNFL temporal quadrant            2.51                           0.951 (0.924--0.969)
  RNFL superior quadrant            2.40                           0.972 (0.956--0.982)
  RNFL nasal quadrant               2.90                           0.937 (0.904--0.960)
  RNFL inferior quadrant            2.48                           0.977 (0.964--0.985)
  **Inter-visit reproducibility**                                  
  RNFL average thickness            2.71                           0.952 (0.928--0.968)
  RNFL temporal quadrant            3.38                           0.961 (0.942--0.974)
  RNFL superior quadrant            3.84                           0.922 (0.885--0.948)
  RNFL nasal quadrant               5.25                           0.845 (0.781--0.896)
  RNFL inferior quadrant            3.97                           0.955 (0.934--0.971)

The Bland--Altman plots (Figures [2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"}) obtained for peripapillary RNFL and macular GC-IPL thicknesses intra and inter-visits showed no evidence of bias in intra- and inter-visit mean differences in both RNFL and GC-IPL average thickness measurements.

![Bland--Altman plot of intra-visit peripapillary retinal nerve fiber layer (RNFL) thickness.](fneur-08-00359-g002){#F2}

![Bland--Altman plot of inter-visit peripapillary retinal nerve fiber layer (RNFL) thickness.](fneur-08-00359-g003){#F3}

![Bland--Altman plot of intra-visit macular ganglion cell-inner plexiform layer (GC-IPL) average thickness.](fneur-08-00359-g004){#F4}

![Bland--Altman plot of inter-visit macular ganglion cell-inner plexiform layer (GC-IPL) average thickness.](fneur-08-00359-g005){#F5}

In the subgroup analysis (Tables S1--S4 in Supplementary Material), we found that the values of CoV and ICC for GC-IPL and RNFL measurements were similar between subjects with AD and MCI, indicating both GC-IPL and RNFL measures had similar reliability performance between AD and MCI groups.

Discussion {#S4}
==========

The results obtained from this study highlight that GC-IPL and RNFL measurements obtained using SD-OCT were repeatable and reproducible in cognitively impaired patients with no significant cognitive decline over 1 year.

Optical coherence tomography is a promising and potential tool to assess neurodegenerative diseases such as dementia. Recent clinical studies have shown that thinning of the GC-IPL and RNFL in the retina is present in patients with MCI and AD when compared with normal controls ([@B6]--[@B10]), suggesting that OCT measurements may be used as a biomarker to assess neuronal loss. However, there was doubt if these changes were due to disease mechanisms or could be attributed to measurement variability or natural progression due to age ([@B30], [@B31]) and other factors unrelated to cognitive neurodegeneration. There was also no available evidence on whether RNFL and GC-IPL continued to degenerate in cognitively impaired patients with relatively stable conditions, if thinning was independent or associated with cognitive performance.

Numerous studies have examined reproducibility and repeatability of using OCT to assess RNFL measurement in normal healthy subjects, glaucoma, retinal diseases, and hypertensive eyes, with ICCs ranging from around 0.90 to 0.99, and CoV ranging from around 0.41 to 2.24% ([@B19]--[@B25]). Furthermore, one study reported the repeatability of OCT in measurement of retinal and RNFL thicknesses in 75 patients with AD, with satisfactory results (mean CoV of 4.78% and ICC of \>0.905) ([@B23]). Our study provides additional data showing that both intra-visit repeatability and inter-visit reproducibility was excellent, with inter-visit ICCs ranging from 0.845 to 0.961, and the range of CoV was 2.71--5.25%. In addition, we also extended our study population to those with MCI, with similar repeatable and reproducible OCT measurement.

Furthermore, in studies employing similar imaging techniques on patients with MCI and AD, patients had a reduction of 12.40--20.00 µm in the RNFL average thickness ([@B12]), a reduction of 27.10--30.09 µm in the RNFL superior quadrant thickness, and a reduction of 3.42--4.99 µm in average GC-IPL thickness ([@B11]) when compared with normal controls. Given the results of our study, which showed a CoV of 2.71% for the inter-visit RNFL average thickness and 1.24% for inter-visit GC-IPL average thickness, the acceptable and expected variability of the measurements for average thickness of RNFL (mean 90.23 µm) and GC-IPL (mean 76.75 µm) are about 2.44 and 0.95 µm, respectively.

Since reduction in both RNFL and GC-IPL thicknesses in both MCI and AD patients was much larger than the expected variation in persons with stable cognitive statuses, it suggests that retinal degeneration observed by these previous studies is likely to be due to disease, rather than measurement variability. However, whether reduction of RNFL and GC-IPL thicknesses in patients is indicative or predictive of future cognitive decline needs to be further explored in prospective studies.

Hence, this study examined and concluded that the repeatability and reproducibility of the data obtained patients with MCI and AD from both intra and inter-visit OCT scans across three visits were excellent. Importantly, this shows that it can accurately and reliably detect retinal changes in patients and these changes could be directly attributed to the patients' disease process, rather than measurement variability due to OCT. It also provides strong validation data from previous studies showing RNFL and GC-IPL thinning in patients with neurodegenerative diseases.

Strengths of the study include standardized imaging protocols and strict quality control to ensure that OCT scans obtained were of consistent quality and using standardized objective cognitive function assessment tools to monitor cognitive decline in subjects. Furthermore, there was the availability of a SD-OCT for use to collect data from the involved patients and the inclusion of patients with varying degrees of cognitive impairment. Moreover, we also ruled out confounding ocular pathologies to ensure any observed variance is not due to ocular pathology.

However, a limitation of our study was that only patients with good quality scans across all three-study visits were included for analysis. Hence, these results may not be generalizable to non-compliant patients, especially those with severe cognitive impairment. However, strict inclusion criteria were implemented to prevent introducing variability to measurements from factors other than cognitive function or pathological neurodegeneration. Also, the strict criteria ensures that the data collected and analyzed were accurate and in line with our study goals as much as possible. Second, the current OCT model lacked eye-tracking capabilities. This might affect the reliability of the measurements obtained. Another limitation of our study was the elimination of ungradable scans and eyes with retinal pathology. This may underestimate and limit the application of the data to real-world situations. Finally, all images were taken at a single site, and this might have introduced a degree of bias.

In conclusion, OCT is a commonly and widely used diagnostic tool and has aided in the diagnosis and follow-up for many patients worldwide. Its use and role in clinical assessment are ever expanding. This study showed that both RNFL and GC-IPL measurements had good reproducibility over 1 year in elderly patients with no decline in cognitive function. It gives great promise to the ability of OCT to detect changes in the retinal layers that could be directly associated with the disease process in patients with MCI and AD, suggesting that SD-OCT may be useful in uncovering pathological changes in retinal neuronal and axonal layers associated with cognitive decline.
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